Every few months, someone in a regulatory affairs forum asks a version of the same question: does rolling review actually save time, or does it just move the same amount of work earlier? It’s a fair thing to wonder as the term gets used loosely. Some people confuse it with priority review. Others assume it means the FDA is somehow reviewing a partial drug application and reaching partial conclusions. Neither is quite right.
The FDA rolling review process is a specific administrative mechanism built into the drug approval pathway, and it has clear eligibility rules. It has a defined submission structure, and real tradeoffs. If you’re a sponsor weighing whether to use it, or a regulatory professional trying to explain it to a project team, this blog will help you understand exactly what’s happening at each stage.
Let’s walk through what rolling review is, who can use it, how the submission is structured section by section, and where sponsors tend to underestimate the operational load it creates. We’ll also look at where rolling review fits alongside other expedited pathways, since it rarely stands alone.
Table of Contents
What Rolling Review Actually Means
In a standard New Drug Application (NDA) or Biologics License Application (BLA), a sponsor assembles the entire application (nonclinical data, clinical data, chemistry, manufacturing and controls, or CMC, and administrative sections) and submits it all at once. FDA’s official filing clock, and the review timeline that follows, starts from that single submission date.
Rolling review changes the sequencing, not the standard of evidence. Instead of waiting until every module is complete, a sponsor submits finished modules as they become available. The nonclinical package might go in first, CMC data a few months later, and clinical data after that. FDA reviews each completed section as it arrives, rather than waiting for the full module to be completed.
One detail trips people up constantly: FDA does not consider the application officially and fully received until the final section is submitted. Everything before that point is preliminary review activity. The formal review clock associated with the complete application doesn’t start until the last piece lands.
Who Qualifies for Rolling Review
Rolling review isn’t available on request. It’s tied to a small set of expedited program designations, and a sponsor generally has to already hold one of them before rolling review becomes an option.
The designations that most commonly carry rolling review eligibility:
- Fast Track designation: This is granted under the Food and Drug Administration Modernization Act, for drugs treating serious conditions with potential to address an unmet medical need
- Breakthrough Therapy designation: This is assigned for drugs showing preliminary clinical evidence of substantial improvement over available therapies
- Certain other programs where FDA has agreed, on a case-by-case basis, that rolling review is appropriate
Getting one of these designations doesn’t automatically make you eligible for rolling review. It has to be discussed and agreed with FDA, ideally at or before the pre-BLA or pre-NDA meeting. FDA’s own guidance recommends bringing it up as early as possible in that conversation, not after the first module is already drafted.
It’s also worth noting that Fast Track and Breakthrough Therapy designations open the door to other expedited tools too, including Priority Review and Accelerated Approval. Rolling review is often just one piece of a broader expedited development strategy, not a standalone request.
How the Process Works, Step by Step
1. Confirm designation status.
Before anything else, the sponsor needs an active Fast Track or Breakthrough Therapy designation, or another basis FDA has accepted for rolling review.
2. Raise rolling review at the pre-BLA/pre-NDA meeting.
This is the point where the sponsor and FDA agree, in writing, that a rolling submission is appropriate for this particular application. FDA’s guidance is explicit that this conversation should happen at or before that meeting, not mid-submission.
3. Plan the submission sequence.
Sponsors typically organize submissions around complete eCTD modules, commonly nonclinical, then CMC, then clinical, though the order can vary based on which data matures first. FDA generally expects each submitted piece to be a whole section (an entire CMC module, for example), not a partial one, unless there’s specific agreement otherwise.
4. Submit sections as they’re completed.
Each portion goes in as it’s finished. FDA begins substantive review of each piece as it arrives, flagging questions and information requests along the way rather than saving all feedback for the end.
5. Respond to information requests in parallel.
This is where things get demanding. The sponsor’s regulatory and clinical teams are often responding to FDA questions on an already-submitted module while simultaneously finishing the next one. That overlap is the real operational cost of rolling review.
6. Submit the final section.
Once the last module is in, FDA considers the application fully received. This is when the official review clock for the complete application starts running.
7. FDA completes review and files the application.
With all sections in hand, FDA moves through filing and the standard review process from that point forward.
Pro Tip: FDA’s guidance notes that once a rolling review is agreed to, all portions of the application should ideally be submitted withvin one year of the first piece. If that timeline slips too far, FDA may pause review of the earlier sections, since staff availability and review bandwidth aren’t held open indefinitely.
Rolling Review Vs Standard Submission
| Factor | Standard Submission | Rolling Review |
| Submission structure | Entire application submitted at once | Sections submitted as completed |
| Review clock start | Begins at full submission | Begins once final section is received |
| FDA agreement required | Not applicable | Yes, agreed in advance |
| Eligibility | Any sponsor | Fast Track, Breakthrough Therapy, or FDA-agreed cases |
| Operational complexity | Lower, single coordinated filing | Higher, multiple deadlines and parallel workstreams |
| Draft sections accepted | Not applicable | No, each submitted section must be complete and reviewable |
| Typical use case | Standard development timelines | Serious conditions, unmet medical need, urgent programs |
What FDA Is Actually Doing During a Rolling Review
It helps to picture what’s happening on FDA’s side, since sponsors sometimes assume the agency is quietly waiting until everything arrives before doing any real work. That’s not the case.
Review divisions assign staff to evaluate each completed section as it comes in. If the nonclinical package raises questions, the review team can send those questions back well before the clinical section even exists. This is part of why FDA’s guidance frames rolling review as tied to early and frequent communication, not just an administrative filing convenience.
That said, review teams aren’t reaching final conclusions on isolated sections. A CMC review, for instance, might flag issues that only make full sense once clinical data arrives. Rolling review front-loads the conversation, but the overall approval decision still depends on the complete picture.
Common Mistakes Sponsors Make
Assuming designation alone grants rolling review.
Fast Track and Breakthrough Therapy designations make rolling review possible, they don’t grant it automatically. Sponsors sometimes plan a rolling submission strategy before actually confirming FDA’s agreement, which creates avoidable rework.
Submitting incomplete modules.
FDA’s expectation is that each submitted section is complete and reviewable on its own, not a draft or partial module submitted to “hold a place in line.” Submitting incomplete sections can slow review rather than speed it up.
Underestimating the parallel workload.
Regulatory, clinical, and CMC teams often end up managing FDA information requests on earlier modules while still finishing later ones. Without careful project management, this creates the kind of bottleneck rolling review is supposed to avoid.
Letting the submission timeline drift.
FDA’s general expectation is that all sections land within about a year of the first submission. Programs that stretch this out risk having earlier review work paused.
Treating rolling review as a substitute for a strong data package.
Rolling review changes sequencing. It does not lower FDA’s evidentiary bar. A weak clinical package submitted on a rolling basis is still a weak clinical package.
Conclusion
Rolling review solves a specific, narrow problem: it lets sponsors avoid sitting on finished data while waiting for the last piece of a large application to catch up. It doesn’t lower FDA’s bar for evidence, and it isn’t available without an underlying expedited designation and FDA’s explicit agreement.
For programs with a genuine unmet medical need and the operational capacity to manage submissions and information requests in parallel, it can meaningfully change the shape of the review timeline. For programs without that operational bandwidth, it can just as easily create more coordination problems than it solves.
Sponsors weighing whether to pursue rolling review are usually better served by mapping out the full submission sequence early, well before the pre-BLA or pre-NDA meeting, so the conversation with FDA starts from a realistic plan rather than a hopeful one.
Navigating expedited FDA pathways, sourcing the comparator needed for a data submission, or coordinating clinical trial supply on a rolling timeline all come with their own operational demands. Spring Bio Solution works alongside sponsors, CROs, and CDMOs managing exactly these kinds of complex, time-sensitive programs.
If your team is planning a rolling submission or needs support sourcing comparators or reference-listed drugs for a related trial, reaching out to Spring Bio Solution can simplify this task for you, as we are a one-stop solution for comparator sourcing.
Frequently Asked Questions
What is the FDA rolling review process?
It’s a mechanism that allows a sponsor to submit completed sections of an NDA or BLA to FDA as they’re finished, rather than waiting to submit the entire application in one filing.
Which drugs are eligible for rolling review?
Drugs with Fast Track designation or Breakthrough Therapy designation are typically eligible, along with any other program FDA specifically agrees to on a case-by-case basis.
Does rolling review shorten the total FDA review timeline?
Not automatically. The official review clock for the complete application starts once the final section is submitted. What rolling review does is let FDA begin evaluating earlier sections and raise questions, well before that point.
Can a sponsor request rolling review at any time?
The request itself is tied to an existing Fast Track or Breakthrough Therapy designation, and the rolling structure needs to be agreed with FDA, ideally discussed at or before the pre-BLA or pre-NDA meeting.
What happens if the submission timeline drags on too long?
FDA’s general guidance is that all sections should be submitted within roughly a year of the first piece. If that window is exceeded, FDA may pause review of the already-submitted sections.
Is rolling review the same as Priority Review or Accelerated Approval?
No. Rolling review governs how and when the application is submitted. Priority Review shortens FDA’s target timeline for reviewing a complete application. Accelerated Approval allows approval based on a surrogate endpoint. A single drug can potentially use more than one of these programs together.
Why would a sponsor choose rolling review over a standard submission?
It allows FDA feedback on completed sections to happen earlier, which can help sponsors resolve manufacturing or nonclinical questions before the clinical package is even finalized, rather than facing all of FDA’s questions at once near the end of a standard review.
